171 related articles for article (PubMed ID: 9377120)
1. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis.
Moore RD; Chaisson RE
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Sep; 16(1):15-21. PubMed ID: 9377120
[TBL] [Abstract][Full Text] [Related]
2. Incremental cost-effectiveness analysis of intravenous ganciclovir versus oral ganciclovir in the maintenance treatment of newly diagnosed cytomegalovirus retinitis in patients with AIDS.
Rachlis A; Smaill F; Walker V; Hotchkies L; Jones A
Pharmacoeconomics; 1999 Jul; 16(1):71-84. PubMed ID: 10539123
[TBL] [Abstract][Full Text] [Related]
3. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection.
Paltiel AD; Scharfstein JA; Seage GR; Losina E; Goldie SJ; Weinstein MC; Craven DE; Freedberg KA
Med Decis Making; 1998; 18(2 Suppl):S93-105. PubMed ID: 9566470
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of treatment administration strategies of ganciclovir for cytomegalovirus retinitis in HIV/AIDS patients in Thailand: a simulation study.
Teerawattananon K; Iewsakul S; Yenjitr C; Ausayakhun S; Yenjitr W; Mugford M; Teerawattananon Y
Pharmacoeconomics; 2007; 25(5):413-28. PubMed ID: 17488139
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of preventing AIDS-related opportunistic infections.
Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
[TBL] [Abstract][Full Text] [Related]
6. An economic exploration of oral and intravenous ganciclovir in the induction and maintenance treatment of AIDS-related cytomegalovirus retinitis.
Davies L; Maynard A
Int J STD AIDS; 1996 Oct; 7(6):415-21. PubMed ID: 8940670
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing.
Rose DN; Sacks HS
AIDS; 1997 Jun; 11(7):883-7. PubMed ID: 9189213
[TBL] [Abstract][Full Text] [Related]
8. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
[TBL] [Abstract][Full Text] [Related]
9. Ganciclovir. A pharmacoeconomic review of its use as intravenous or oral maintenance therapy in the management of cytomegalovirus retinitis in patients with AIDS.
Perry CM; Davis R
Pharmacoeconomics; 1997 Aug; 12(2 Pt 1):209-28. PubMed ID: 10169672
[TBL] [Abstract][Full Text] [Related]
10. An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients.
Sullivan SD; Mozaffari E; Johnson ES; Wolitz R; Follansbee SE
Clin Ther; 1996; 18(3):546-58. PubMed ID: 8829030
[TBL] [Abstract][Full Text] [Related]
11. Eye implants shown superior to IV for retinitis.
AIDS Alert; 1997 Oct; 12(10):115-7. PubMed ID: 11364717
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of systemic treatments for cytomegalovirus retinitis in patients with AIDS.
Lee TA; Sullivan SD; Veenstra DL; Ramsey SD; Steger PJ; Malinverni R; Pleil AM; Williamson T
Pharmacoeconomics; 2001; 19(5 Pt 2):535-50. PubMed ID: 11465299
[TBL] [Abstract][Full Text] [Related]
13. Protease inhibitors linked to drop in CMV retinitis.
AIDS Alert; 1997 Aug; 12(8):92-4. PubMed ID: 11364475
[TBL] [Abstract][Full Text] [Related]
14. FDA approves oral ganciclovir as first drug to prevent CMV disease. Food and Drug Administration.
Baker R
BETA; 1995 Dec; ():8. PubMed ID: 11363015
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice.
Mauskopf JA; Richter A; Annemans L; Maclaine G
Pharmacoeconomics; 2000 Sep; 18(3):239-51. PubMed ID: 11147391
[TBL] [Abstract][Full Text] [Related]
16. Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panel.
Martin DF; Dunn JP; Davis JL; Duker JS; Engstrom RE; Friedberg DN; Jaffe GJ; Kuppermann BD; Polis MA; Whitley RJ; Wolitz RA; Benson CA
Am J Ophthalmol; 1999 Mar; 127(3):329-39. PubMed ID: 10088745
[TBL] [Abstract][Full Text] [Related]
17. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients.
Oppenheimer F; Gonzalez-Molina M; Rubio M
Clin Transplant; 2007; 21(4):441-8. PubMed ID: 17645702
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal ganciclovir maintenance injection for cytomegalovirus retinitis: efficacy of a low-volume, intermediate-dose regimen.
Teoh SC; Ou X; Lim TH
Ophthalmology; 2012 Mar; 119(3):588-95. PubMed ID: 22137552
[TBL] [Abstract][Full Text] [Related]
19. The epidemiology, treatment patterns, and costs of cytomegalovirus retinitis in the post-haart era among a national managed-care population.
Mahadevia PJ; Gebo KA; Pettit K; Dunn JP; Covington MT
J Acquir Immune Defic Syndr; 2004 Aug; 36(4):972-7. PubMed ID: 15220705
[TBL] [Abstract][Full Text] [Related]
20. Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS.
Kempen JH; Frick KD; Jabs DA
Pharmacoeconomics; 2001; 19(12):1199-208. PubMed ID: 11772155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
